Literature DB >> 25184913

Epidemiological profile of nonmelanoma skin cancer in renal transplant recipients: experience of a referral center.

Flávia Regina Ferreira1, Marilia Marufuji Ogawa2, Luiz Fernando Costa Nascimento1, Jane Tomimori2.   

Abstract

BACKGROUND: Nonmelanoma skin cancer is the most common form of cancer in humans and also the malignant disease that is increasingly common among kidney transplant recipients.
OBJECTIVE: To determine the epidemiological characteristics of renal transplant recipients with nonmelanoma skin cancer seen at a referral transplantation center.
METHODS: Cross-sectional descriptive study with renal transplant recipients presenting nonmelanoma skin cancer, treated at a transplantation referral center between 08/01/2004 and 08/31/2009. Analyzed variables were: gender, age, skin phototype, occupational and recreational sun exposure, use of photoprotection, personal and family history of non-melanoma skin cancer, clinical type and location, time between transplantation and the appearance of the first nonmelanoma skin cancer, occurrence of viral warts, timing of transplantation, type of donor, cause of kidney failure, previous transplants, comorbidities, pre-transplant dialysis, type and duration of dialysis.
RESULTS: 64 subjects were included. Males--71.9%; low skin phototypes (up to Fitzpatrick III)--89%; mean age--57.0 years--and mean age at transplant--47.3 years; sun exposure--67.2% occupational--and 64.1% recreational; photoprotection--78.2% (although only 34.4% in a regular manner); squamous cell carcinoma--67.2%; squamous cell carcinoma/basal cell carcinoma ratio--2:1; personal history of nonmelanoma skin cancer--25%--and family history--10.9%; location at photoexposed area--98.4%; average latency time between transplantation and first nonmelanoma skin cancer appearance--78.3 months; viral warts (HPV) after transplant--53.1%; average timing of transplantation--115.5 months; living donor--64.1%; triple regimen (antirejection)--73.2%; comorbidities--92.2%; pre-transplant dialysis--98.4%; hemodialysis--71.7%; average duration of dialysis--39.1 months; previous transplants--3.1%; hypertension as cause of renal failure--46.9%.
CONCLUSION: This study allowed the epidemiological characterization of a population of kidney transplant recipients with nonmelanoma skin cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25184913      PMCID: PMC4155952          DOI: 10.1590/abd1806-4841.20142590

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  14 in total

1.  Nonmelanoma skin cancer.

Authors:  Todd W Ridky
Journal:  J Am Acad Dermatol       Date:  2007-05-21       Impact factor: 11.527

2.  Non-melanoma skin cancer risk in the Queensland renal transplant population.

Authors:  H M Ramsay; A A Fryer; C M Hawley; A G Smith; P N Harden
Journal:  Br J Dermatol       Date:  2002-11       Impact factor: 9.302

3.  The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study.

Authors:  J N Bouwes Bavinck; D R Hardie; A Green; S Cutmore; A MacNaught; B O'Sullivan; V Siskind; F J Van Der Woude; I R Hardie
Journal:  Transplantation       Date:  1996-03-15       Impact factor: 4.939

Review 4.  Risk factors for basal cell carcinoma: a case-control study.

Authors:  M Maia; N G Proença; J C de Moraes
Journal:  Rev Saude Publica       Date:  1995-02       Impact factor: 2.106

5.  Nonmelanoma skin cancer after renal transplantation: a single-center experience in 1736 transplantations.

Authors:  George Zavos; Nikolaos P Karidis; Gerasimos Tsourouflis; John Bokos; Konstantinos Diles; George Sotirchos; Eleni Theodoropoulou; Alkiviadis Kostakis
Journal:  Int J Dermatol       Date:  2011-07-26       Impact factor: 2.736

Review 6.  Human papillomaviruses and non-melanoma skin cancer.

Authors:  Catherine A Harwood; Charlotte M Proby
Journal:  Curr Opin Infect Dis       Date:  2002-04       Impact factor: 4.915

7.  Basal cell carcinoma: an updated epidemiological and therapeutically profile of an urban population.

Authors:  Roberta Lopes Bariani; Fábio Xerfan Nahas; Marcus Vinícius Jardini Barbosa; Andréia Bufoni Farah; Lydia Masako Ferreira
Journal:  Acta Cir Bras       Date:  2006-03-21       Impact factor: 1.388

8.  Cancer after kidney transplantation in the United States.

Authors:  Bertram L Kasiske; Jon J Snyder; David T Gilbertson; Changchun Wang
Journal:  Am J Transplant       Date:  2004-06       Impact factor: 8.086

9.  A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients.

Authors:  M J Fuente; M Sabat; J Roca; R Lauzurica; M T Fernández-Figueras; C Ferrándiz
Journal:  Br J Dermatol       Date:  2003-12       Impact factor: 9.302

10.  Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients.

Authors:  Helen M Ramsay; Sarah M Reece; Anthony A Fryer; Andrew G Smith; Paul N Harden
Journal:  Transplantation       Date:  2007-08-15       Impact factor: 4.939

View more
  3 in total

1.  Hypovitaminosis D in patients undergoing kidney transplant: the importance of sunlight exposure.

Authors:  Cristiane F Vilarta; Marianna D Unger; Luciene M Dos Reis; Wagner V Dominguez; Elias David-Neto; Rosa M Moysés; Silvia Titan; Melani R Custodio; Mariel J Hernandez; Vanda Jorgetti
Journal:  Clinics (Sao Paulo)       Date:  2017-07       Impact factor: 2.365

2.  HLA alleles in renal transplant recipients with nonmelanoma skin cancer in southeastern Brazil.

Authors:  Clarissa Schmidt Rogel; Fabiana Covolo de Souza-Santana; Elaine Valim Camarinha Marcos; Marilia Marufuji Ogawa; Geovana Basso; Jane Tomimori
Journal:  An Bras Dermatol       Date:  2019-07-29       Impact factor: 1.896

3.  Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40 year retrospective study in Croatia.

Authors:  Nikolina Bašić-Jukić; Tajana Borlinić; Deša Tešanović; Ivica Mokos; Ivan Krešimir Lukić; Zrinka Bukvić Mokos
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.